Home > Boards > US Listed > Biotechs >

Celsion Corporation (CLSN)

CLSN RSS Feed
Add CLSN Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 12/1/2019 10:25:11 PM - Followers: 267 - Board type: Free - Posts Today: 0


 

Celsion is now funding branded oncology drug development through a fastest-path-to-commercialization strategy for ThermoDox®, its proprietary thermally sensitive liposomal encapsulation of doxorubicin. We are also identifying opportunities to expand our range of therapeutic indications through investments in our core technology platform.

To maximize global commercialization following approval, Celsion is developing distribution alliance opportunities for ThermoDox in key geographic markets. Once these are finalized we will seek to acquire additional platform technology and chemotherapeutic candidates to add to our development pipeline.

Celsion will continue to strengthen its prospects for the future through its research, license and commercialization agreements with leading institutions, among others; the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic and the North Shore Long Island Jewish Health System.


http://celsion.com/ 

Low Temperature Sensitive Liposome - LTSL

Video of this technology in action: http://origin-qps.onstreammedia.com/origin/shareholder/Archive/wmdemand/hostedfiles/30924CLN_MOA.wmv



 

CHART:








 



 

 

CLSN
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CLSN News: Celsion’s New Subsidiary in China to Serve as Beachhead for Commercializing ThermoDox® in China and Southeast Asia 12/18/2019 08:00:10 AM
CLSN News: Celsion Receives $2.0 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program 12/17/2019 08:00:10 AM
CLSN News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 12/06/2019 04:18:19 PM
CLSN News: Statement of Changes in Beneficial Ownership (4) 11/20/2019 11:29:52 AM
CLSN News: Current Report Filing (8-k) 11/14/2019 04:26:46 PM
PostSubject
#16524   The Heat Trial had been recruiting Biobonic 12/01/19 10:25:11 PM
#16523   Here is the HEAT subgroup data timeline I GD 11/28/19 01:05:56 AM
#16522   I was looking for some thing close to GD 11/27/19 12:20:07 PM
#16521   Some cutouts from the 3Q cc Biobonic 11/17/19 08:36:01 PM
#16520   Got me some europtiger 11/14/19 02:37:12 PM
#16519   Wording in Celsion PR not well thought out. Biobonic 11/10/19 09:27:08 AM
#16518   I have never heard of an IA stopping exwannabe 11/10/19 07:34:16 AM
#16517   Yes, I stand corrected Biobonic 11/08/19 08:18:42 PM
#16516   Is 70 or less ? stockweiser 11/08/19 05:58:18 PM
#16515   I have emailed Celsion's IR Biobonic 11/08/19 12:09:32 PM
#16514   The primary outcome measures is OS Biobonic 11/08/19 11:58:47 AM
#16513   Is the primary end point pfs? stockweiser 11/07/19 11:47:31 AM
#16512   A Director of the Company bought 4,000 shares Biobonic 11/04/19 09:40:59 PM
#16511   Thank you stockweiser 11/04/19 04:37:50 PM
#16510   Surprised you sold stockweiser 11/04/19 04:27:07 PM
#16509   I am very dispointed at the PR today, GD 11/04/19 02:37:10 PM
#16508   Here is the YouTube link to Dr. David veni vidi vici 11/04/19 02:02:27 PM
#16507   If we look at the >90 min subgroug GD 11/03/19 09:04:16 PM
#16506   Thanks Found the https://clincancerres.aacrjournals.org/content/24/1/73 article h Biobonic 11/03/19 07:53:01 PM
#16505   Sorry, I deleted it after I listend to GD 11/02/19 10:20:07 PM
#16504   The 285 >45 min subgroup is divided in GD 11/02/19 10:11:51 PM
#16503   Do you have that YouTube link to the stockweiser 11/02/19 09:41:20 PM
#16502   Looking at the HEAT Study Biobonic 11/02/19 09:41:14 PM
#16501   May be I am reading into too much, GD 11/02/19 09:28:19 PM
#16500   I am very bullish with CLSN, I constantly GD 11/02/19 04:31:14 PM
#16499   You still bullish on CLSN? stockweiser 11/02/19 04:15:19 PM
#16498   CEO is not totally honest, the Q rate GD 11/02/19 04:09:39 PM
#16497   I don't get that though they said they stockweiser 11/02/19 02:44:18 PM
#16496   I think Aspire demand to rewrite the $10M GD 11/02/19 01:46:58 PM
#16495   What is your take on the Aspire deal? stockweiser 11/01/19 08:10:26 PM
#16494   I think I wrote my opinions here on GD 10/31/19 03:55:58 PM
#16493   True that on DD Biobonic 10/31/19 03:25:51 PM
#16492   Not much time to do DD, we may GD 10/31/19 10:38:13 AM
#16491   Biobonic 10/30/19 08:05:12 PM
#16490   When deciding on treatment, health care providers consider Biobonic 10/30/19 07:50:12 PM
#16489   From the HEAT data, we can see 46% GD 10/30/19 06:37:31 PM
#16488   Here is some additional info on side effects. Biobonic 10/30/19 04:31:00 PM
#16487   I mean side effects which are strongly relate GD 09/27/19 12:00:58 PM
#16486   Thermodex arm has strong side effects? stockweiser 09/27/19 11:50:40 AM
#16485   By the way, I firmly believe CLSN has GD 09/27/19 10:46:19 AM
#16484   I did, many times. He recommends IV Thermodox GD 09/27/19 10:29:02 AM
#16483   Did you watch YouTube video of inventor of stockweiser 09/27/19 09:57:46 AM
#16482   I am willing to believe Prof. Lencioni statement GD 09/26/19 11:05:21 PM
#16481   Find out in about 6 weeks stockweiser 09/26/19 09:21:44 PM
#16480   Look at page 20 on the subgroup >45 GD 09/26/19 01:11:28 PM
#16479   Thanks for that informal response I look forward stockweiser 09/23/19 09:29:08 PM
#16478   ON Q4 and Q1 CC, CEO said less GD 09/21/19 08:31:04 PM
#16477   I thought first look was less than 50%? stockweiser 09/21/19 03:21:29 PM
#16476   The first look P value to stop for GD 09/18/19 02:43:04 PM
#16475   Do you have any idea what is the GD 07/28/19 01:20:11 AM
PostSubject